Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro

Thrombosis Research

Volumn 93, Issue 3, 1999, Pages 137-143

  Inoue, Teruo ^a   Sohma, Ryoichi ^a   Morooka, Shigenori ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

ADP; Cilostazol; GPIIb IIIa; P selectin; Platelet activation

Indexed keywords

CILOSTAZOL; EPITOPE; FIBRINOGEN RECEPTOR; MEMBRANE PROTEIN; PADGEM PROTEIN; PHOSPHODIESTERASE;

ADULT; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG INHIBITION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE;

ANTIGENS, CD; BLOOD PLATELETS; CELLS, CULTURED; HUMANS; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET MEMBRANE GLYCOPROTEINS; TETRAZOLES;

EID: 0033082537     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00172-8     Document Type: Article

References (21)

1. Nishi T., Tabusa F., Tanaka T., Shimizu T., Kanbe T., Kimura Y., Nakagawa K. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. II. 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull. 31:1983;1151-1157.
2. Akiyama H., Kubo S., Shimizu T. The absorption, distribution and excretion of a new antithrombotic and vasodilating agent, cilostazol, in rat, rabbit, dog and man. Arzneim-Forsch/Drug Res. 35:1985;1124-1132.
3. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimantal thrombosis. Arzneim-Forsch/Drug Res. 35:1985;1144-1149.
4. Phillips D.R., Charo I.F., Parise L.V., Fitzgerald L.A. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 71:1988;831-843.
5. Shattil S.J., Hoxie J.A., Cunningham M., Brass L.F. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem. 260:1985;11107-11114.
6. x, and sulfated glycans modulate this binding. Biochem Biophys Res Commun. 181:1991;1223-1230.
7. Hamburger S.A., McEver R.P. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 75:1990;550-554.
8. Palabrica T., Lobb R., Furie B.C., Aronovitz M., Bebjamin C., Hsu Y.M., Sajer S.A., Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 359:1992;848-851.
9. Stenberg P.E., McEver R.P., Shuman M.A., Jaques Y.V., Bainton D.F. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 101:1985;880-886.
10. Nieuwenhuis H.K., van Oosterhout J.J.G., Rozenmuller E., van Iwaarden F., Sixma J.J. Studies with a monoclonal antibody against activated platelets:evidence that a secreted 53,000- molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 70:1987;838-845.
11. Nomura S., Shouzu A., Kagawa H., Nishikawa M., Inada M., Furukawa S. Effects of cilostazol on platelet-derived microparticle generation in patients with diabetes. Thromb Haemost. Suppl):1997;468.
12. Wilentz J.R., Sanborn T.A., Haudenschild C.C., Vareli C.R., Ryan T.G., Faxon D.P. Platelet accumulation in experimental angioplasty. time course and relation to vascular injury Circulation. 75:1987;635-642.
13. Cunningham D.A., Kumar B., Siegel B.A., Gilula B.A., Totty W.G., Welch M.J. Aspirin inhibition of platelet deposition at angioplasty sites. Demonstration by platelet scintigraphy Radiology. 151:1984;487-490.
14. Gawaz M., Neumann F.-J., Ott I., May A., Schömig A. Platelet activation and coronary stent implantation. Effect of antithrombic therapy Circulation. 94:1996;279-285.
15. Clowes A.W., Reidy M.A., Clowes M.M. Mechanism of stenosis after arterial injury. Lab Invest. 49:1983;208-215.
16. Clowes A.W., Reidy M.A., Clowes M.M. Kinetics of cellular proliferation after arterial injury. Lab Invest. 49:1983;327-333.
17. Liw M.W., Roubin G.S., King S.B. III Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia Circulation. 79:1989;1374-1387.
18. Inoue T., Hoshi K., Fujito T., Sakai Y., Morooka S., Sohma R. Early detection of platelet activation after coronary angioplsty. Coron Artery Dis. 7:1996;529-534.
19. Inoue T., Sakai Y., Morooka S., Hayashi T., Takayanagi K., Takabatake Y. Expression of polymorphonuclear leukocyte adhesion molecules and its clinical significance in patients treated with percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 28:1996;1127-1133.
20. Inoue T., Sakai Y., Fujito T., Hoshi K., Hayashi T., Takayanagi K., Morooka S. Clinical significance of neutrophil adhesion molecules expression after coronary angioplasty on the development of restenosis. Thromb Haemost. 79:1998;54-58.
21. Inoue T., Sakai Y., Fujito T., Hoshi K., Hayashi T., Takayanagi K., Morooka S., Sohma R. Expression of activation dependent platelet membrane protein after coronary stenting. a comparison with balloon angioplasty Circulation. 94(Suppl I):1996;1-260.